" class="no-js "lang="en-US"> Yannick Pletan - Medtech Alert
Wednesday, June 18, 2025
Yannick Pletan

Yannick Pletan

About Yannick Pletan

With a continuous track record of successful achievements in the Pharma and Biotech Industry for several years, in several companies, positions, cultures, and by building, leading and engaging highly professional teams, the most salient feature of my career remains that it has been a fair balance between Corporate and Affiliate positions, Expertise and Management, R&D/Science and Business. With this, I had the incredible opportunity to cover the whole spectrum of a drug life cycle, and face almost all possible challenges, while developing a robust international as well as diverse network. Leadership and Entrepreneurship have been constant features in all roles.
I currently act as a senior consultant for the biotech sector mainly. I seat on the Board of Directors of several listed and private companies including DEINOVE, NH THERAGUIX, NFL Biotechnologies, and on the Surveillance Committee of CROSSJECT and OTR3. I am the Chief Medical Officer and General Manager of ACTICOR-BIOTECH, and the Chief Medical Officer of TREEFROG Therapeutics. I am a Senior Lecturer at the University of Lyon 1 and at ESSEC Business School.

Related Story

Acticor Biotech Announces the Enrollment of the First US Patient in Its Phase 2/3 Study ACTISAVE for the Treatment of Stroke

September 27 2022

ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the […]

Acticor Biotech Obtains "PRIME" Status From the European Medicines Agency for Glenzocimab in the Treatment of Stroke

July 25 2022

ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the […]